Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BRSK2 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | DOK6 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | TDG | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | EPM2A | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
mRNA | MTNR1A | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
mRNA | CA6 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
mRNA | RAB1A | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-06 |
mRNA | CRMP1 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
mRNA | TAF5 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
mRNA | MAMDC4 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |